2020-11-18 08:00
November 18, 2020 -- Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020). The PROMISE Study is evaluating the...
2020-11-17 15:35
Biovica, active in cancer diagnostics, today announced that new DiviTum®TKa results from a large SWOG Cancer Research Network study further strengthen DiviTum®TKa’s monitoring capabilities within metastatic breast cancer. The study, known...
2020-10-23 08:00
Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world's largest breast cancer symposium, SABCS, in early December. The abstracts...
2020-06-17 08:00
Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration...
2020-05-22 09:45
Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors. The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey...
2020-05-11 08:15
Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors...
2020-05-06 10:25
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00. Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is...
2020-04-29 11:38
Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After...
2020-04-08 08:00
The main purpose of including DiviTum® in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum®, in patients with hormone positive metastatic breast cancer treated with today’s...
2020-03-25 08:30
“As DiviTum® is approaching commercialization we are strengthening the team. Robert brings insights from cancer diagnostics as well as therapeutics and has an excellent track record of successful product launches which will be valuable when...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects